Background
==========

Molecular-based allergy (MA) diagnostics are used to identify patient sensitization to individual allergen components. Despite a recent consensus statement, the clinical utility of MA diagnostics in routine practice remains unclear.

Aim
===

To review the cost and usage patterns of MA diagnostics at a regional level and to estimate the clinical value of such testing strategies.

Methods
=======

Laboratory data on Northern Ireland MA diagnostics ordering between 2010 and 2013 was obtained. Data specific to Regional Immunology Service patients from 2013 was further interrogated. A retrospective review of case records from adults (n=70) and children (n=53) was carried out to determine the impact of MA test results.

Results
=======

MA testing has increased annually since its introduction in 2010. Spending on MA diagnostics exceeded £20,000 in 2013. Increases in test numbers were observed across a range of allergen groups during the time period and suggests routine ordering (Figure [1](#F1){ref-type="fig"}). Analysis of request sources indicated a surge in test numbers across 5 key user hospital units (Figure [2](#F2){ref-type="fig"}). Additionally, a marked increase in MA diagnostics orders from non-specialist sources was noted.
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Use of MA diagnostics introduced a mean increase in cost of 156% in adults (range 11%-900%) and 197% in children (range 9%-600%)(Table [1](#T1){ref-type="table"}). Review of individual cases indicated that MA diagnostics had no specific impact on diagnosis or management in 78.6% of adults and 83.0% of children.

                                                                       Adults (n=70)   Children (n=53)
  -------------------------------------------------------------------- --------------- -----------------
  **Mean age (sd)**                                                    31.9 (12.3)     9.2 (4.2)
                                                                                       
  **% cost increase with MA (range)**                                  156 (11-900)    197 (9-600)
                                                                                       
  **MA test results altered management, n(%)**                         6 (8.6)         7 (13.2)
                                                                                       
  **MA test results provided useful diagnostic support, n(%)**         9 (12.8)        2 (3.7)
                                                                                       
  **MA test results had no impact on diagnosis or management, n(%)**   55 (78.6)       44 (83)

Discussion
==========

This study suggests that the use of MA diagnostics is entering routine clinical practice and is associated with a cost premium. The minimal clinical impact of these testing modalities argues for the establishment of demand management programs in resource-constrained environments.
